Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been assigned an average rating of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $10.00.

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Metagenomi from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Metagenomi in a research report on Monday, December 22nd. Finally, Zacks Research upgraded shares of Metagenomi from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th.

Metagenomi Stock Performance

MGX opened at $1.67 on Friday. Metagenomi has a one year low of $1.23 and a one year high of $4.00. The stock has a market capitalization of $62.68 million, a P/E ratio of -0.70 and a beta of 0.50. The business’s 50-day simple moving average is $1.85 and its 200-day simple moving average is $2.04.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.05. Metagenomi had a negative return on equity of 43.19% and a negative net margin of 287.06%.The firm had revenue of $8.66 million for the quarter, compared to the consensus estimate of $7.82 million. On average, equities research analysts forecast that Metagenomi will post -2.46 EPS for the current fiscal year.

Institutional Trading of Metagenomi

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC lifted its position in Metagenomi by 53.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company’s stock worth $32,000 after acquiring an additional 7,458 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Metagenomi by 1,840.0% during the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock worth $36,000 after purchasing an additional 14,389 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Metagenomi by 508.5% during the third quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock worth $44,000 after purchasing an additional 15,682 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Metagenomi during the third quarter worth $64,000. Finally, Nuveen LLC purchased a new position in Metagenomi in the 1st quarter valued at $86,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.